Cadrenal Therapeutics, Inc. Form 8-K Summary
Reporting date: July 12, 2023; the filing was signed July 14, 2023. The company reported a material private placement of securities. Cadrenal is incorporated in Delaware, trades under CVKD on Nasdaq Capital Market, and identifies as an emerging growth company.
Transaction and Key Financial Terms
- The company agreed to sell 1,300,000 shares of common stock and pre-funded warrants exercisable for up to 2,985,715 shares.
- Investors also received common warrants exercisable for up to 4,285,715 shares of common stock or pre-funded warrants.
- The private placement closed on July 14, 2023, generating approximately $7.5 million of gross proceeds, before placement-agent commissions and offering expenses.
- The combined purchase price was $1.75 per share with accompanying common warrants, or $1.7499 per pre-funded warrant with accompanying common warrants.
- Pre-funded warrants have a $0.0001 exercise price and do not expire until exercised in full. Common warrants have a $1.75 exercise price and expire five and one-half years after issuance.
- The company intends to use net proceeds for working capital.
- H.C. Wainwright & Co. acted as placement agent and is entitled to a 7.5% cash fee on gross proceeds, a 1.0% management fee, reimbursement of certain expenses and legal fees, and warrants to purchase 278,571 shares at $2.1875 per share.
Capitalization, Liquidity and Financial Results
The filing does not provide revenue, net income or loss, operating cash flow, cash balance, margins, debt balances, or other financial statement metrics. The financing increases liquidity by the amount of net proceeds, but the filing does not state the final net proceeds after fees and expenses or the company’s resulting cash runway.
Material Changes and Dilution
- The transaction materially expands the company’s potential share count through the issued shares, pre-funded warrants, common warrants and placement-agent warrants.
- Exercise of all investor pre-funded and common warrants could result in issuance of up to 7,271,430 additional shares or equivalent securities, subject to applicable terms and the 9.99% beneficial ownership limitation.
- The company is restricted, subject to limited exceptions, from issuing additional common stock or common stock equivalents or filing certain registration statements for 60 days following the registration effectiveness deadline.
- Company directors and officers agreed to restrictions on transferring, pledging or selling their shares for 60 days following the registration effectiveness deadline.
Registration, Outlook and Risks
- The company agreed to file a resale registration statement within 15 days of July 12, 2023, and to seek effectiveness within 45 days, or within 75 days if the SEC reviews and provides written comments.
- Failure to meet specified registration milestones or maintain an effective registration statement may require liquidated damages of 1% of the investor’s aggregate investment per 30-day period, capped at 6%.
- The securities were sold in a private placement under Regulation D to an institutional accredited investor and were not registered under the Securities Act. Resale requires registration or an applicable exemption.
- The filing provides no formal revenue, earnings, cash-flow or operating guidance.
- Key risks include dilution from warrant exercises, the company’s ability to deploy the financing effectively, registration delays and related liquidated damages, restrictions on future capital raising, and the absence of disclosed financial information in this filing.
Investor Verification Items
- Verify the final net proceeds after placement-agent commissions, advisory fees and offering expenses.
- Review the company’s latest balance sheet and cash runway to assess the impact of the financing on liquidity.
- Confirm the number of shares outstanding after the closing and the potential dilution from all warrants.
- Check the filing and effectiveness status of the resale registration statement and any related liquidated damages.
- Review the warrant agreements for adjustment provisions, cashless exercise rights and beneficial ownership limitations.
- Assess the company’s subsequent filings for use of proceeds, operating milestones and additional financing needs.